Study combines lapatinib with cetuximab to overcome resistance in EGFR-driven tumors

May 16, 2012 in Cancer

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib. Findings from this phase I study will be presented at the American Society of Clinical Oncology annual meeting in Chicago, June 1st through 5th.

Cetuximab works by blocking the (EGFR) found on the outside of a cell. In cancers such as colon, head and neck, and lung, when cetuximab stops EGFR signaling, the machinery inside the cell doesn't get the signal to grow, in turn causing it to die. However, cancer cells can become resistant to cetuximab when the EGFR receptor combines with a related receptor HER2 (ErbB2) -- which cetuximab can't block. Once again, the cell gets the signal to grow. Lapatinib however blocks HER2 and EGFR from the inside of cancer cells.

" are good at developing ways around our treatments, including new targeted therapies such as cetuximab." says John Deeken, M.D., a medical oncologist at Georgetown Lombardi Comprehensive Cancer Center. "By combining different targeted therapies, we hope to be able to overcome such and turn off the cancer cell signal to grow."

Deeken, an expert in how cells or process drugs, took the information learned from these recent pre-clinical studies and designed a novel clinical trial – combining cetuximab, which blocks EGFR, with lapatinib which works inside the cell and shuts down . GlaxoSmithKline provided lapatinib for the study and additional financial support for the study.

Cetuximab, marketed as Erbitux, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer and head and neck cancer. Lapatinib, marketed as Tykerb, is FDA-approved for the treatment of some types of breast cancer.

Sixteen patients whose tumors are driven by EGFR were enrolled in the study and received the established dose of (intravenously once a week). Lapitinib, a drug taken orally on a daily basis, was given in escalating doses. Twelve of thirteen patients were evaluable for toxicities (side effects). The most common side effects of the combination were rash and diarrhea, both of which can be managed with supportive medications and care.

"While this study isn't designed to evaluate whether or not this combination of drugs works, we have seen some positive signs of clinical activity," Deeken says.

Of nine patients evaluable for response (completed at least two cycles of treatment), two had a partial response (more than 30 percent tumor shrinkage),and two had prolonged stable disease of 2 cycles or more, for a clinical benefit rate of 44 percent.

Phase II studies to test this combination in colon as well as head and neck cancer patients are under development, Deeken says.

Provided by Georgetown University Medical Center search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

Cancer created 19 minutes ago | popularity not rated yet | comments 0

Protein preps cells to survive stress of cancer growth and chemotherapy

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

Cancer created 29 minutes ago | popularity not rated yet | comments 0 | with audio podcast

Frequent heartburn may predict cancers of the throat and vocal cord

Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data ...

Cancer created 56 minutes ago | popularity not rated yet | comments 0

Key find for early bladder cancer treatment

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0

Cold plasma successful against brain cancer cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...

Cancer created 3 hours ago | popularity 5 / 5 (2) | comments 0 | with audio podcast


Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Regenerating spinal cord fibers may be treatment for stroke-related disabilities

A study by researchers at Henry Ford Hospital found "substantial evidence" that a regenerative process involving damaged nerve fibers in the spinal cord could hold the key to better functional recovery by most stroke victims.

The secret lives, and deaths, of neurons

As the human body fine-tunes its neurological wiring, nerve cells often must fix a faulty connection by amputating an axon—the "business end" of the neuron that sends electrical impulses to tissues or other ...

Defective cellular waste removal explains why Gaucher patients often develop Parkinson's disease

Gaucher disease causes debilitating and sometimes fatal neurodegeneration in early childhood. Recent studies have uncovered a link between the mutations responsible for Gaucher disease and an increased risk ...

Anxious men fare worse during job interviews, study finds

Nervous about that upcoming job interview? You might want to take steps to reduce your jitters, especially if you are a man.

Breakthrough on Huntington's disease

Researchers at Lund University have succeeded in preventing very early symptoms of Huntington's disease, depression and anxiety, by deactivating the mutated huntingtin protein in the brains of mice.